Prostate Cancer Awareness: Know Your Options

Looking forward to football season in September? This month also marks Prostate Cancer Awareness Month. Just as play options are important to football players, it is also important for you to know what the options are for prostate cancer. Prostate cancer is one of the most common cancers among men in the United States. Most prostate cancers grow slowly and do not cause health problems. Men with a greater chance of getting prostate cancer are older men, African-American men, and men with a family history of prostate cancer. If you think you may be at high risk for prostate cancer, talk to your doctor about what screening or treatment approach is best for you. CDC is making strides in bringing awareness to prostate cancer and providing information about your options. Take a look at our newest resources.

"Should I Get Tested for Prostate Cancer?" is a new motion graphic video that helps men understand their prostate cancer screening options.
Treatment Decision Dashboard is an interactive web-based tool that provides a walk-through of each treatment option for low- or intermediate-risk prostate cancer. The dashboard, developed by the University of Rochester and funded by DCPC, uses graphical examples and provides a side by side comparison of short- and long-term outcomes of common prostate cancer treatments.

CDC's Inside Knowledge Gets VIP Treatment in New York

New York City welcomes CDC with an all-access pass! Throughout September, CDC’s Inside Knowledge: Get the Facts About Gynecologic Cancers campaign, is raising awareness about the five main gynecologic cancers: cervical, ovarian, uterine, vaginal, and vulvar. Check out and share the newest resources.

Digital billboard located in Times Square at 1500 Broadway and 43rd Street, features Inside Knowledge messages on a large 29 x 56 display, and animates between two screens over a : 10 second period. Here it is for everyone who may not get to New York to see it.
The New York Times article," A Woman's Guide to Understanding Gynecologic Cancers," features interviews with gynecological cancer survivors and DCPC’s Dr. Sherri Stewart and encourages women to be tuned in to their bodies. It’s accessible online and on mobile devices.
Recently released Knowledge is Power animated videos are having a major impact across social media platforms with more than 72,000 clicks and an 11.5% click-through rate in just the first three days of their release. (The industry average for click-through rates is 1%). One video focuses on gynecologic cancers in general and the other three discuss cervical, ovarian, and uterine cancers. All videos are available in English and Spanish.

CDC Celebrates Successes with Partners

The National Comprehensive Cancer Control Program, (NCCCP) celebrated its 20th Anniversary with a business meeting and special observance event on September 10-11, 2018 at CDC’s Chamblee and Roybal campuses. Over 120 people attended including national program awardees, CCC National Partners, CDC staff and other featured guests. The NCCCP provides support to all 50 states, the District of Columbia, 8 tribal organizations, and 7 US territories to establish broad-based cancer coalitions, assess the burden of cancer in their communities, determine priorities for cancer prevention and control, and develop and implement customized cancer control plans accordingly. Activities included breakout sessions on topics such as, Selecting the Best Evidence-Based Interventions, Applying the Health Equity Dual Approach, and NCCCP Communications: Telling Your Stories. In addition, local WSB-TV news anchor, Fred Blankenship, moderated reflection panel discussions that included panelists sharing their experiences getting started, gaining appropriate stakeholder buy-in, and fostering the program's growing momentum. Panelists included national partnership representatives from the American College of Surgeons Commission on Cancer, Intercultural Cancer Council, National Cancer Institute, and Strategic Health Concepts; representatives from the first six states to receive comprehensive cancer control funding from CDC (Colorado, Massachusetts, Michigan, North Carolina, Northwest Portland Area Indian Health Board and Texas); and current and former CDC employees. Dr. Abdul Saied Calvino and Ms. Hiam Hamade both received Carol Friedman Awards for their exemplary cancer control activities to address health equity. This award honors the late Dr. Carol Friedman (the former Chief of the CDC branch that manages the NCCCP) and is presented annually in recognition of successful comprehensive cancer control activities in field. The event was a huge success! Learn more about comprehensive cancer control programs.

International Spotlight: CDC's National Program of Cancer Registries

The National Cancer Registrars Association (NCRA) is helping promote cancer knowledge through an international campaign, Future of Cancer Care. NCRA highlights success stories from CDC’s National Program of Cancer Registries (NPCR) showing how cancer registry data are being used nationwide. The campaign includes partners such as Vice President Joe Biden and Dr. Jill Biden, the Biden Cancer Initiative, American Society of Clinical Oncology, American Society for Radiation Oncology, Stand Up to Cancer, Tesaro, Varian, IBA Worldwide, American Cancer Society, National Institutes of Health, and many others. Distribution networks reaching millions globally, include an insert in USA Today (September 13, 2018), leading industry conferences, and digital platforms such as websites, e-newsletters, and social media. Find out more about cancer registry data.

Clinical Trial Uses New Technology for Breast Cancer Screening

A large National Cancer Institute-funded clinical trial to answer important questions about 2-D versus 3-D mammography is open and recruiting women in clinics across the United States and in Canada. The Tomosynthesis Mammographic Imaging Screening Trial, known as TMIST, needs 165,000 women ages 45 to 74 to compare the current standard for mammograms (digital 2-D mammography) to tomosynthesis (3-D mammography) and is being headed by Etta Pisano, M.D., and the ECOG-ACRIN clinical trials group. The trial will answer whether the newer technology will reduce the rates of life-threatening breast cancers. Women enrolled in TMIST are randomly assigned to tomosynthesis or 2D mammography, and most will be screening once a year for 5 years; some post-menopausal women without additional risk will be screened every other year. There is funding available for uninsured women who wish to participate in TMIST. For more information, visit the TMIST study website.